Coronavirus Update: Gilead Says 'Inappropriate Characterizations' In Remdesivir Trial Flop Leak

Plus: J&J Finds Manufacturing Partner, AZ To Investigate Heart Complications

The leaked abstract suggests remdesivir provides no benefits for patients - but analysts say conclusions are hard to draw from underpowered trial.

Vials_Remdesivir
Three Phase III readouts are expected in the next few weeks, which should provide a clearer picture on remdesivir

Data from a trial in China of Gilead Sciences Inc.’s antiviral treatment remdesivir have been posted by accident online by the World Health Organization, showing that the treatment did not improve the condition of patients with severe COVID-19 or reduce the presence of the virus in the bloodstream.

The study also found the remdesivir arm produced more discontinuations due to adverse events, raising safety concerns.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip